Scholars@Duke
Jason Andrew Somarelli

Jason Andrew Somarelli

Assistant Professor in Medicine
Medicine, Medical Oncology
jason.somarelli@duke.edu
Box 3053, Durham, NC 27710
3044 GSRBI, LaSalle Street, Durham, NC 27710

Scholarly Works - Conferences

Assessing the impact of PCSK9 inhibition in small cell lung cancer with novel DLL3-targeted bispecific T-cell engager therapy.

Conference Journal of Clinical Oncology · June 1, 2026 e20135Background: B-specific T-cell engagers (BiTEs) such as tarlatamab, have improved upon the efficacy and durability of response in small cell lung cancer (SCLC). However, an unmet need remains due to the known “immune-cold” microenvironment and immune ... Full text Cite

Abstract 2291: Exposure to plastic additives suggests potential androgen receptor agonism in prostate cancer

Conference Cancer Research · April 3, 2026 AbstractIntroduction:Plastic is the most abundant human-made substance in the world, and routine ingestion represents a global ... Full text Cite

Abstract 5844: Novel inhibition of transcriptional cyclin-dependent kinases, CDK12/13, using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Conference Cancer Research · April 3, 2026 AbstractIntroduction:Cell proliferation is a hallmark of cancer growth, and regulation of transcription and translation is key ... Full text Cite

Inhibition of transcriptional cyclin-dependent kinases, CDK12/13, as a treatment for colorectal cancer with CDK12 upregulation.

Conference Journal of Clinical Oncology · June 2025 e15722Background: Cell proliferation is a hallmark of cancer growth, and regulation of transcription and translation is key t ... Full text Cite

Efficacy of plogosertib (CYC149462), a novel orally bioavailable PLK1 inhibitor, on patient-derived models of colorectal cancer.

Conference Journal of Clinical Oncology · February 2025 209Background: Colorectal cancer (CRC) is the third most common cancer in adults in the United States. Given the relative rap ... Full text Cite

Abstract 1085: Exploiting bioenergetic vulnerabilities in chemotherapy resistant osteosarcoma

Conference Cancer Research · March 22, 2024 AbstractBACKGROUND: Osteosarcoma (OS) is the most common bone cancer in children and young adults. Standard treatment involves chemotherapy and surgical resection, yet nearly 4 in 10 patients experience dise ... Full text Cite

Abstract 6642: Exploring the x-ray psoralen activated cancer therapy mechanism of action in a genetically engineered mouse model of soft tissue sarcoma

Conference Cancer Research · March 22, 2024 AbstractBACKGROUND: Psoralen is a natural ultraviolet activated compound that has been used for over 70 years to treat skin cancer, psoriasis, and vitiligo. Recently, to expand its use beyond external treatm ... Full text Cite

Efficacy of fadraciclib (CYC065), a novel dual CDK2/9 inhibitor, on patient-derived models of colorectal cancer

Conference Journal of Clinical Oncology · January 1, 2024 Background: Colorectal cancer (CRC) is the third most common type of cancer among adults in the United States. Given the heterogeneous nature of the disease and the limited number of treatments available, there is an unmet need to identify new therapeutic ... Full text Cite

MicroOrganoSpheres as a clinically applicable precision oncology platform for the discovery of novel therapies in colorectal cancer.

Conference Journal of Clinical Oncology · June 1, 2023 3592 Background: Patient-derived models of cancer, such as cell lines, patient-derived organoids, and patient-derived xenografts, are useful models of patient response in the clinic. However, these models are often not clinically ... Full text Cite

Therapeutic potential of dual CDK12 and 13 inhibition in colorectal cancer.

Conference Journal of Clinical Oncology · June 1, 2023 e15601 Background: To date, studies on cyclin-dependent kinase inhibitors in colorectal cancer (CRC), such as targeting CDK4/6 with Palbociclib, have shown little to no clinical benefit. However, tumor profiling of CRC has shown ... Full text Cite

Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry.

Conference Prostate Cancer Prostatic Dis · September 2022 BACKGROUND: Prostate cancer is a clinically and molecularly heterogeneous disease, with highest incidence and mortality among men of African ancestry. To date, prostate cancer patient-derived xenograft (PCPDX) models to study this disease have been difficu ... Full text Open Access Link to item Cite

Abstract A114: Characterization of a metastatic prostate cancer xenograft derived from a patient of African ancestry

Conference Cancer Epidemiology, Biomarkers & Prevention · June 1, 2020 AbstractBackground: Prostate cancer (PCa) is a clinically and molecularly heterogeneous disease, with differences in incidence and mortality among and between racial groups, which grade and stage only partia ... Full text Cite

Abstract B038: Convergent hormone therapy resistance mediated by stress/dormancy-like pathways in prostate cancer

Conference Cancer Research · August 15, 2018 AbstractBackground: Novel agents that inhibit the androgen receptor (AR), including abiraterone acetate and enzalutamide, have significantly prolonged life in many men with metastatic castration-resistant pr ... Full text Cite

Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.

Conference Journal of Clinical Oncology · February 20, 2018 160 Background: Radium-223 is a targeted alpha therapy that improves survival in men with mCRPC. The biologic basis for radium-223 efficacy is not completely understood. We hypothesized that PC osteomimicry, a form of epithelial ... Full text Cite

A precision medicine strategy to identify the FGFR pathway as a novel target in colorectal cancer liver metastasis.

Conference Journal of Clinical Oncology · February 1, 2018 660 Background: Colorectal cancer liver metastasis (CRCLM) continues to be a major health problem and despite extensive efforts to develop new drugs, median survival remains at a mere 30 months. The purpose of our study is 1. Dev ... Full text Cite

Radiation Induces Epithelial-Mesenchymal Transition in an In Vitro Mammary Carcinoma Tumor Model

Conference International Journal of Radiation Oncology*Biology*Physics · October 2013 Full text Cite

Abstract P4-06-07: Isoform specific antibodies against the fibroblast growth factor receptor 2 have predictive and therapeutic implications in the treatment of human breast cancers

Conference Cancer Research · December 15, 2012 AbstractBackground: Aberrant induction of the epithelial to mesenchymal transition cascade (EMT) has a defining role in shaping cancer malignancy. Despite the complexity of this process, the alternative spli ... Full text Cite